Sanofi posted a stronger first‑quarter top line as it navigated a leadership reshuffle. Net sales reached 10.51 billion euros ($12.30 billion), a rise of about 14% on a constant‑currency basis. The boost came from recently launched products and the integration of acquired assets across its global portfolio, reinforcing momentum in Europe and emerging markets.

Operating profit, the metric Sanofi tracks closely, climbed nearly 11% to 2.97 billion euros. Analysts had penciled in 10.22 billion euros of revenue and 2.85 billion euros of profit, according to Var‑Research. The outperformance reflects cost efficiencies and higher demand for its immunology franchise and expanding use in respiratory indications during the quarter.

The board confirmed that Paul Hudson will step down, with Merck KGaA chief Belen Garijo slated to take the helm later this year. Garijo inherits the task of sustaining Dupixent’s momentum while sourcing new growth engines. Investors will watch how swiftly the new CEO can translate sales strength into long‑term earnings.

Overall, the earnings beat underscores Sanofi’s ability to deliver growth despite executive turnover. The stronger top line bolsters its cash flow, giving the company leeway to fund pipeline projects and potential acquisitions. Market participants can now price in a more resilient near‑term outlook for the French pharma giant.